Deleterious clinical effects of transfusion immunomodulation: Proven beyond a reasonable doubt - Commentary

Transfusion

Volumn 45, Issue SUPPL. 2, 2005, Pages

  Triulzi, Darrell J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACADEMIC ACHIEVEMENT; BLOOD TRANSFUSION; CAREER; FLOW CYTOMETRY; FUNDING; HUMAN; IMMUNOMODULATION; LEARNING; LEUKAPHERESIS; NOTE; OUTCOMES RESEARCH; PHYSICIAN ASSISTANT EDUCATION; TEACHING;

EID: 33745288161     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2005.00529.x     Document Type: Note

References (4)

1. Collier AC, Kalish LA, Busch MP, et al. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA 2001;285:1592-601.
2. Triulzi DJ, Meyer EM, Donnenberg AD. WBC subset analysis of WBC-reduced platelet components. Transfusion 2000;40:771-80.
3. Fung MK, Rao N, Rice J, et al. Leukoreduction in the setting of open heart surgery: a prospective cohort-controlled study. Transfusion 2004;44:30-5.
4. Fung M, Moore F, Ridenour M, Mook WJ, Triulzi DJ. Clinical outcomes of reverting from leukoreduced to non-leukoreduced blood in cardiac surgery [abstract]. Transfusion 2004;44:131A 2A.